San Diego, CA (PRWEB) September 16, 2013
Nasseo, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has approved its TiArray™ Dental Implant System for commercial sale in the U.S. It is the first commercial application of Nasseo’s proprietary surface modification technology, which was initially developed over 8 years out of UC San Diego Bioengineering and Materials Science Departments, and the Bio-Implant Laboratory at Lund University in Sweden. The inflammation (“peri-implantitis”) that many patients suffer in reaction to existing dental implants is currently a significant cause of both bone loss and dental implant failure over time. Patients and doctors alike are seeking better performing implants which lower inflammation and promote faster healing.
The TiArray™ Dental Implant System was developed to address a gap in medical care that is currently adding significant costs to the US healthcare system: the failure of dental implants. The $1B+ US dental implant market is growing quickly as clinicians move away from dentures and bridges. However, existing dental implants often fail, requiring repeated clinical visits and additional implants, which is expensive for patients and an inefficient use of clinician time. Due to high dental implant failure rates and growing peri-implantitis concerns, certain high-risk patient populations (e.g. heavy smokers) are being advised against implants altogether. Nasseo aims to address these concerns and provide a longer lasting dental implant.
Dr. Garrett Cale Smith, Co-Founder and CEO, says “Achieving the significant milestone of FDA approval allows us to continue to increase the value of our technology by running clinical trials with key opinion leaders at leading centers. The FDA approval of the Nasseo TiArray™ Dental Implant System is an important step toward our goal of p
Copyright©2012 Vocus, Inc.
All rights reserved